Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging

Xiaohan Yan, Mingming Zhu, Qi Feng, Yunqi Yan, Jiangchen Peng, Xitao Xu, Antao Xu, Zhihua Ran, Xiaohan Yan, Mingming Zhu, Qi Feng, Yunqi Yan, Jiangchen Peng, Xitao Xu, Antao Xu, Zhihua Ran

Abstract

Background and aim: Data on the radiologic evaluation of perianal fistulizing Crohn's disease (PFCD) naïve to anti-tumor necrosis factor therapy are scarce, especially in Asian populations. We assessed the effectiveness of infliximab (IFX) on PFCD and explored predictors of 'deep remission' based on clinical and radiologic assessments.

Methods: Patients with Crohn's disease and active anal fistulas attending our care center for IFX therapy were prospectively enrolled. Each patient underwent clinical examination according to the Fistula Drainage Assessment Index, endoscopy for assessment of Crohn's Disease Activity Index (CDAI) and Perianal Crohn's Disease Activity Index (PCDAI), magnetic resonance imaging (MRI) to determine Van Assche score and Ng score, and laboratory tests up to 2 weeks prior to the start of and up to 2 weeks after the sixth IFX therapy (Week 32).

Results: Among 38 patients treated with IFX, 52.6% achieved clinical remission based on the Fistula Drainage Assessment Index and 42.1% achieved deep remission based on Ng score. Van Assche score (from 14.5 ± 4.26 to 7.36 ± 7.53), CDAI (from 170 ± 92 to 71 ± 69) and PCDAI (from 7.45 ± 2.65 to 2.44 ± 3.20) decreased significantly after six IFX treatments. The only predictor of deep remission was simple fistula (P =0.004, odds ratio = 3.802, 95% confidence interval: 1.541-9.383).

Conclusions: IFX has been shown to have appreciable effectiveness in Chinese patients with PFCD. MRI is the gold standard for evaluating PFCD, but Van Assche score has some limitations.

Keywords: Crohn’s disease; infliximab; magnetic resonance imaging; perianal fistula.

Figures

Figure 1.
Figure 1.
Van Assche scores were significantly reduced after six infliximab (IFX) treatments, from 14.5 ± 4.26 to 7.36 ± 7.53
Figure 2.
Figure 2.
Patient ratios of the six components (complexity of fistula tracks, location relative to the sphincters, extension, hyperintensity on T2-weighted imaging, presence of abscesses and rectal wall involvement) of the Van Assche score on initial and follow-up magnetic resonance imaging

References

    1. Maconi G, Gridavilla D, Vigano C.. Perianal disease is associated with psychiatric co-morbidity in Crohn’s disease in remission. Int J Colorectal Dis 2014;29:1285–90.
    1. Beaugerie L, Seksik P, Nion-Larmurier I. et al. Predictors of Crohn’s disease. Gastroenterology 2006;130:650–6.
    1. Hellers G, Bergstrand O, Ewerth S. et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980;21:525–7.
    1. Schwartz DA, Loftus EV, Tremaine WJ. et al. Response to infliximab in Crohn’s disease: genetic analysis supporting expression profile the natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–80.
    1. Tang LY, Rawsthorne P, Bernstein CN.. Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 2006;4:1130–4.
    1. Makowiec F, Jehle EC, Starlinger M.. Clinical course of perianal fistulas in Crohn’s disease. Gut 1995;37:696–701.
    1. Molendijk I, Nuij VJ, van der Meulen-de Jong AE. et al. Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 2014;20:2022–8.
    1. Marzo M, Felice C, Pugliese D. et al. Management of perianal fistulas in Crohn’s disease: an up-to-date review. World J Gastroenterol 2015;21:1394–403.
    1. Juncadella AC, Alame AM, Sands LR. et al. Perianal Crohn’s disease: a review. Postgrad Med 2015;127:266–72.
    1. Ran Z. Diagnosis and Treatment Strategy of Inflammatory Bowel Disease. Shanghai: Chinese Science Press, 2015.
    1. Lightner AL, Shen B.. Perioperative use of immunosuppressive medication in patients with Crohn’s disease in the new ‘biological era’. Gastroenterol Rep (Oxf) 2017;5:165–77.
    1. Ingle SB, Loftus EV Jr. The natural history of perianal Crohn’s disease. Dig Liver Dis 2007;39:963–9.
    1. Tozer P, Ng SC, Siddiqui MR. et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis 2012;18:1825–34.
    1. Gecse KB, Bemelman W, Kamm MA. et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014;63:1381–92.
    1. Van Assche G, Dignass A, Reinisch W. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4:63–101.
    1. Gecse KB, Sebastian S, Hertogh G. et al. Results of the fifth scientific workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn’s disease-the unmet needs. J Crohns Colitis 2016;10:758–65.
    1. Best WR, Becktel JM, Singleton JW. et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439–44.
    1. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27–32.
    1. Present DH, Rutgeerts P, Targan S. et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405.
    1. Van Assche G, Vanbeckevoort D, Bielen D. et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003;98:332–9.
    1. Ng SC, Plamondon S, Gupta A. et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas. Aliment Pharmacol Ther 2009;30:757–66.
    1. Castaño-Milla C, Chaparro M, Saro C. et al. Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015;49:34–40.
    1. Hanauer SB, Feagan BG, Lichtenstein GR, ACCENT I Study Group et al.Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
    1. Sands BE, Anderson FH, Bernstein CN. et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85.
    1. Thomassin L, Armengol-Debeir L, Charpentier C. et al. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn’s disease. World J Gastroenterol 2017;23:4285–92.
    1. Ng SC, Plamondon S, Gupta A. et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am J Gastroenterol 2009;104:2973–86.
    1. Tougeron D, Savoye G, Savoye-Collet C. et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn’s disease. Dig Dis Sci 2009;54:1746–52.
    1. Karmiris K, Bielen D, Vanbeckevoort D. et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn’s disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011;9:130–6.
    1. Medrano LM, Taxonera C, González-Artacho C. et al. Response to Infliximab in Crohn’s disease: genetic analysis supporting expression profile. Mediators Inflamm 2015;2015:318207..
    1. Kugathasan S, Werlin SL, Martinez A. et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000;95:3189–94.
    1. Lionetti P, Bronzini F, Salvestrini C. et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 2003;18:425–31.
    1. Panes J, Jairath V, Levesque BG.. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017;152:362–73e363.
    1. Rayen J, Currie T, Gearry RB. et al. The long-term outcome of anti-TNF alpha therapy in perianal Crohn’s disease. Tech Coloproctol 2017;21:119–24.
    1. Tozer PJ, Burling D, Gupta A. et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 2011;33:5–22.
    1. Shenoy-Bhangle A, Nimkin K, Goldner D. et al. MRI predictors of treatment response for perianal fistulizing Crohn disease in children and young adults. Pediatr Radiol 2014;44:23–9.
    1. Dejaco C, Harrer M, Waldhoer T. et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003;18:1113–20.
    1. Viscido A, Habib FI, Kohn A. et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003;17:1263–71.
    1. Topstad DR, Panaccione R, Heine JA. et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003;46:577–83.
    1. Gionchetti P, Dignass A, Danese S. et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis 2017;11:135–49.
    1. Lichtenstein GR, Diamond RH, Wagner CL. et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210–26.
    1. Van Assche G, Magdelaine-Beuzelin C, D’Haens G. et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861–8.
    1. Korelitz BI, Adler DJ, Mendelsohn RA. et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993;88:1198–205.
    1. Davidov Y, Ungar B, Bar-Yoseph H. et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis 2017;11:549–55.
    1. Yarur AJ, Kanagala V, Stein DJ. et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther 2017;45:933–40.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する